Prothena Corporation plc (PRTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $409.26M
Last updated: Nov 17, 2026 at 4:15 PM ET
Prothena Corporation plc (PRTA) Statistics
Prothena Corporation (PRTA) has a market cap of $409.26M and an enterprise value of $137.89M. Revenue grew 347.44% over the last 12 months from the 12 months before. It holds $271.37M more cash than debt, 66.31% of its market cap.
Total Valuation
Enterprise value is 66.31% below the market cap, as cash exceeds debt.
| Market Cap | $409.26M |
|---|---|
| Enterprise Value | $137.89M |
| Latest price (Nov 17, 2026) | $8.26 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 8.1x and 1.6x. Its year-end P/S ranged from 5.5x to 775.6x from 2017 to 2025.
| Forward P/E | 73.6x |
|---|---|
| P/S Ratio | 8.1x |
| Forward P/S | 5.4x |
| P/B Ratio | 1.6x |
Price Statistics
The stock is down 16.82% over 52 weeks and trades 2.59% below its 50-day average.
| Beta (1Y) | 1.06 |
|---|---|
| 52-Week Change | -16.82% |
| 1-Month Change | -2.59% |
| 3-Month Change | -11.09% |
| 6-Month Change | -8.93% |
| 5-Year Change | -84.70% |
| 10-Year Change | -82.29% |
| Total Return (1Y) | -16.82% |
| Total Return (3Y CAGR) | -37.63% |
| Total Return (5Y CAGR) | -31.47% |
| Return vs SPY (1Y) | -31.83% |
| Max Drawdown (1Y) | -31.45% |
| Max Drawdown (3Y) | -88.74% |
| Sharpe Ratio (1Y) | -0.47 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $8.48 |
| 200-Day Average | $9.17 |
| 52-Week Range | $7.73 to $11.80 |
| RSI (14 Days) | 47.9 |
| Average Volume (20 Days) | 452.73K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 23.95x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 23.95x |
|---|---|
| Quick Ratio | 23.95x |
| Debt / Equity | 0.00x |
| Interest Coverage | 3.41x |
Returns and Efficiency
Return on equity is -8.91% over the last 12 months, against a 5-year average of -28.55%.
| Return on Equity (ROE) | -8.91% |
|---|---|
| Return on Assets (ROA) | -8.45% |
| ROE (5Y Average) | -28.55% |
| ROA (5Y Average) | -24.52% |
| ROIC (5Y Average) | -76.64% |
| Asset Turnover | 0.17x |
Scores
PRTA has an Altman Z-Score of 11.60, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 11.60 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $52.73M over the last 12 months.
| Revenue | $52.73M |
|---|---|
| Revenue Growth (YoY) | +347.44% |
| Gross Profit | $52.73M |
| Operating Income | -$34.09M |
| Pretax Income | -$23.95M |
| Net Income | -$23.96M |
| Reported EPS (TTM) | -$0.42 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.82% of the $283.52M in total assets.
| Cash and Equivalents | $271.37M |
|---|---|
| Total Debt | $0 |
| Net Cash | $271.37M |
| Net Cash Per Share | $5.28 |
| Working Capital | $262.43M |
| Shareholder Equity | $268.84M |
| Book Value Per Share | $5.23 |
| Total Assets | $283.52M |
| Total Liabilities | $14.68M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $727.04K of capital spending, operating cash flow left -$32.17M of free cash flow.
| Operating Cash Flow | -$31.45M |
|---|---|
| Capital Expenditures | $727.04K |
| Free Cash Flow | -$32.17M |
| FCF Per Share | -$0.63 |
| Depreciation and Amortization | $1.53M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -64.64%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -64.64% |
| Pretax Margin | -45.41% |
| Net Margin | -45.43% |
| FCF Margin | -61.01% |
Growth
Revenue fell 43.57% a year over 3 years.
| Revenue Growth (3Y CAGR) | -43.57% |
|---|---|
| Revenue Growth (5Y CAGR) | +62.56% |
| Book Value Per Share Growth (2Y CAGR) | -29.42% |
| Tangible Book Per Share Growth (2Y CAGR) | -29.42% |
Dividends and Yields
PRTA does not pay a dividend. Its free cash flow yield is -7.57%.
| FCF Yield | -7.57% |
|---|---|
| Buyback Yield | 6.29% |
| Shareholder Yield | 6.29% |
Peer Position
Against 8 similar companies, PRTA has the 2nd highest P/S.
P/S RatioPeer median 3.9x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.48%
| P/S Ratio | 8.1x vs 3.9x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +347.44% vs +13.48% median |
Analyst Forecast
Consensus estimates put revenue growth at -9.82% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -9.82% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PRTA
What is PRTA's market cap?
Prothena Corporation has a market cap of $409.26M. Its enterprise value, which adds debt and subtracts cash, is $137.89M.
How many shares of PRTA are outstanding?
Prothena Corporation has 51.44M shares outstanding. The count is down 4.45% from a year earlier.
Does PRTA pay a dividend?
No. Prothena Corporation does not pay a dividend.
How much debt does PRTA have?
Prothena Corporation has $0 of total debt and $271.37M of cash and equivalents, a net cash position of $271.37M.
PRTA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors